昭衍新藥(603127.SH):擬推2022年A股限制性股票激勵計劃
格隆匯8月15日丨昭衍新藥(603127.SH)公佈2022年A股限制性股票激勵計劃(草案),該計劃公司擬向激勵對象授予140.06萬股限制性股票,涉及的標的股票種類為人民幣A股普通股,約佔該計劃草案公吿時公司股本總額53,419.1429萬股的0.262%。
該計劃授予限制性股票的授予價格為39.87元/股。該激勵計劃授予的激勵對象總人數為611人,包括公司公吿該激勵計劃時在公司(含控股子公司)任職的公司董事、高級管理人員及核心技術(業務)骨幹。
該計劃有效期為限制性股票授予登記之日起至激勵對象獲授的限制性股票全部解除限售或回購註銷完畢之日止,最長不超過48個月。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.